(Q36210252)

English

Possible pathophysiologic mechanisms supporting the superior stroke protection of angiotensin receptor blockers compared to angiotensin-converting enzyme inhibitors: clinical and experimental evidence

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

12 August 2017

1 reference

Europe PubMed Central

Possible pathophysiologic mechanisms supporting the superior stroke protection of angiotensin receptor blockers compared to angiotensin-converting enzyme inhibitors: clinical and experimental evidence (English)

1 reference

Europe PubMed Central

12 August 2017

pathophysiology

1 reference

based on heuristic

inferred from title

author name string

Chrysant SG

1

1 reference

Europe PubMed Central

12 August 2017

publication date

1 December 2005

1 reference

Europe PubMed Central

12 August 2017

Journal of Human Hypertension

1 reference

Europe PubMed Central

12 August 2017

19

1 reference

Europe PubMed Central

12 August 2017

12

1 reference

Europe PubMed Central

12 August 2017

923-931

1 reference

Europe PubMed Central

12 August 2017

https://scigraph.springernature.com/pub.10.1038/sj.jhh.1001916

0 references

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

21 January 2018

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

21 January 2018

Mortality by cause for eight regions of the world: Global Burden of Disease Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

21 January 2018

Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

21 January 2018

The Greater Cincinnati/Northern Kentucky Stroke Study: preliminary first-ever and total incidence rates of stroke among blacks

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

21 January 2018

Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

21 January 2018

Stroke is more common than myocardial infarction in hypertension: analysis based on 11 major randomized intervention trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

21 January 2018

Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent randomized clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

21 January 2018

Modulation of the AT2 subtype receptor gene activation and expression by the AT1 receptor in endothelial cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

21 January 2018

Does angiotensin-II protect against strokes?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

21 January 2018

MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

21 January 2018

Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

21 January 2018

Calcium-channel blockade and cardiovascular prognosis: recent evidence from clinical outcome trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

21 January 2018

Has the role of calcium channel blockers in treating hypertension finally been defined?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

21 January 2018

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

21 January 2018

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

21 January 2018

A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

21 January 2018

Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

21 January 2018

Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

21 January 2018

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

21 January 2018

Ischemic stroke. Impact of a recent myocardial infarction.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

21 January 2018

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

21 January 2018

Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

21 January 2018

The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

21 January 2018

The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

21 January 2018

The effect of losartan on global and focal cerebral perfusion and on renal function in hypertensives in mild early ischaemic stroke

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

21 January 2018

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

21 January 2018

Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

21 January 2018

Angiotensin II decreases mortality rate in gerbils with unilateral carotid ligation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

21 January 2018

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

21 January 2018

Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

21 January 2018

Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

21 January 2018

Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

21 January 2018

Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

21 January 2018

Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

21 January 2018

Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

21 January 2018

Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats: comparison of losartan, candesartan, and valsartan.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

21 January 2018

Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

21 January 2018

Childhood uric acid predicts adult blood pressure: the Bogalusa Heart Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

21 January 2018

Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

21 January 2018

The role of cell surface proteins in platelet stimulation by monosodium urate crystals.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

21 January 2018

Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

21 January 2018

From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

21 January 2018

Uric acid: role in cardiovascular disease and effects of losartan

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

21 January 2018

Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

21 January 2018

Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

21 January 2018

Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

21 January 2018

The impact of serum uric acid on cardiovascular outcomes in the LIFE study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

21 January 2018

Primary Prevention of Ischemic Stroke

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

21 January 2018

Stroke prevention with losartan in the context of other antihypertensive drugs.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

7 January 2021

based on heuristic

inferred from DOI database lookup

Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

7 January 2021

based on heuristic

inferred from DOI database lookup

Angiotensin AT2 receptor stimulation increases survival in gerbils with abrupt unilateral carotid ligation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

7 January 2021

based on heuristic

inferred from DOI database lookup

Blockade of central angiotensin AT(1) receptors improves neurological outcome and reduces expression of AP-1 transcription factors after focal brain ischemia in rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of losartan on cerebral arteries in stroke-prone spontaneously hypertensive rats.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

7 January 2021

based on heuristic

inferred from DOI database lookup

Losartan mediated improvement in insulin action is mainly due to an increase in non-oxidative glucose metabolism and blood flow in insulin-resistant hypertensive patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of losartan on human platelet activation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

7 January 2021

based on heuristic

inferred from DOI database lookup

Vascular changes underlying cerebral lesions in stroke-prone spontaneously hypertensive rats. A serial section study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

7 January 2021

based on heuristic

inferred from DOI database lookup

Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

7 January 2021

based on heuristic

inferred from DOI database lookup

Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

7 January 2021

based on heuristic

inferred from DOI database lookup

Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

7 January 2021

based on heuristic

inferred from DOI database lookup

Allopurinol Normalizes Endothelial Dysfunction in Type 2 Diabetics With Mild Hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001916

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.JHH.1001916

1 reference

Europe PubMed Central

12 August 2017

1 reference

Europe PubMed Central

12 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36210252&oldid=1984430582"